TL;DR
This paper introduces novel fucoidan-chitosan nanoparticles (CFNs) designed to target P-selectin, a key molecule in atherosclerosis. These CFNs not only deliver therapeutic benefits by reducing oxidative stress and inflammation but also demonstrate effective targeting of atherosclerotic plaques, offering a promising new avenue for treating this prevalent cardiovascular disease.
What Problem Does This Paper Address?
Atherosclerosis, a major cause of cardiovascular disease, is driven by inflammation and oxidative stress within artery walls. Current treatments often lack specificity, leading to off-target effects and limited efficacy. Nanoparticles (NPs) offer a promising approach for targeted drug delivery, but many existing NP materials lack intrinsic therapeutic properties and can cause adverse reactions. The authors aim to develop a multifunctional NP that can specifically target atherosclerotic lesions, possess inherent antioxidant and anti-inflammatory capabilities, and overcome the limitations of current therapies.
Methods
The researchers synthesized fucoidan-chitosan nanoparticles (CFNs) through a polycation/polyanion self-assembly approach. They optimized CFN size and stability by varying the chitosan-to-fucoidan ratio and concentrations. Physicochemical characterization was performed using Transmission Electron Microscopy (TEM) and Fourier Transform Infrared Spectroscopy (FTIR).
Key experimental approaches included:
- In vitro antioxidant assays: DPPH, superoxide radical, and hydroxyl radical scavenging activities were measured to assess the CFNs' ability to neutralize reactive oxygen species (ROS).
- Cellular assays:
- Intracellular ROS generation in macrophages (RAW 264.7) was measured using DCFH-DA.
- Foam cell formation induced by oxidized low-density lipoprotein (oxLDL) was assessed using Oil Red O staining.
- Pro-inflammatory cytokine levels (TNF-α, IL-6, IL-1β) and nitric oxide (NO) production in LPS/IFN-γ-stimulated macrophages were quantified using ELISA and commercial kits.
- Apoptosis was detected using Annexin V-PI double staining.
- Cytotoxicity was evaluated using a WST-8 assay on RAW 264.7 cells and mouse vascular endothelial cells (MVECs).
- Cellular uptake of CFNs by macrophages and MVECs was visualized using fluorescence microscopy.
- Targeting and P-selectin interaction studies:
- The effect of a P-selectin inhibitor on CFN uptake by MVECs was assessed via flow cytometry.
- P-selectin expression in MVECs after CFN incubation was analyzed by Western blotting.
- In vivo studies:
- ApoE-/- mice were used to establish an atherosclerosis model.
- CFN targeting to atherosclerotic plaques was evaluated using fluorescence imaging after intravenous injection of FITC-labeled CFNs.
- The therapeutic efficacy of CFNs was assessed by analyzing aortic lesions (ORO staining, H&E, Masson's trichrome), serum inflammatory markers (TNF-α, IL-1β), vascular superoxide anion generation (DHE staining), and P-selectin expression in peripheral blood.
- Long-term safety was evaluated by analyzing hematological parameters, biochemical markers, and histological examination of major organs.
Datasets
Not discussed in the paper. The study primarily relies on experimental data generated from in vitro and in vivo experiments using established cell lines and animal models.
Key Insights and Ideas
- Dual-functionality of CFNs: The CFNs are not just passive carriers; they possess inherent antioxidant and anti-inflammatory properties derived from fucoidan, making them multifunctional.
- P-selectin as a targeted delivery mechanism: The ability of CFNs to bind to P-selectin, a key adhesion molecule in inflammation and thrombosis, allows for specific targeting of atherosclerotic plaques. This is a significant advantage over non-targeted therapies.
- Fucoidan's role in targeting and therapy: Fucoidan, a sulfated polysaccharide, is crucial for both P-selectin binding and its antioxidant/anti-inflammatory effects, highlighting its therapeutic potential.
- Chitosan's role as a stable scaffold: Chitosan provides a stable matrix for the nanoparticles, and its positive charge aids in interaction with negatively charged cell membranes in the vascular wall.
- Effective reduction of atherosclerotic markers: The CFNs demonstrated significant reduction in key markers of atherosclerosis, including plaque area, necrotic core formation, and inflammatory cell infiltration, both in vitro and in vivo.
- Safety profile: The CFNs showed a favorable safety profile, with no significant adverse effects observed in vitro or in vivo, suggesting their potential for clinical translation.
Key Results
- Nanoparticle characteristics: CFNs were synthesized with a size of approximately 150 nm and a positive zeta potential of +25 mV, indicating good stability and potential for interaction with cell membranes.
- Antioxidant activity: CFNs exhibited significant scavenging activity against DPPH, superoxide, and hydroxyl radicals, with a scavenging effect of 74.9% against DPPH radicals at 1.5 mg/mL fucoidan concentration.
- Anti-inflammatory effects: CFNs significantly suppressed the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and nitric oxide in LPS/IFN-γ-stimulated macrophages.
- Foam cell inhibition: CFNs reduced oxLDL-induced foam cell formation in macrophages by approximately 59.5%.
- Apoptosis and Cytotoxicity: CFNs showed anti-apoptotic effects and exhibited low cytotoxicity on both macrophages and MVECs, with cell viability remaining above 90% even at high concentrations.
- Cellular uptake: CFNs were efficiently internalized by both macrophages and MVECs, with uptake increasing with incubation time.
- P-selectin targeting: CFN uptake by MVECs was significantly reduced by P-selectin inhibition, confirming P-selectin-mediated targeting. CFNs also downregulated P-selectin expression in MVECs.
- In vivo plaque targeting: FITC-labeled CFNs showed preferential accumulation in atherosclerotic plaques of ApoE-/- mice, with higher fluorescence intensity observed at 6 hours post-injection compared to 12 hours.
- Therapeutic efficacy in vivo: CFN treatment significantly reduced aortic plaque area, necrotic core formation, and inflammatory markers compared to saline and klotho treatments. They also reduced systemic oxidative stress and inflammation.
- Safety: Long-term safety studies showed no significant adverse effects on major organs, hematological parameters, or biochemical markers.
Limitations and Future Work
- pH sensitivity: While the 3:1 CS:fucoidan ratio showed moderate swelling at pH 6.0, further investigation into the pH response of CFNs in different physiological environments (e.g., oral administration) is needed.
- Organ distribution: While CFNs showed preferential accumulation in plaques, their distribution in other organs was also observed. Further studies could focus on optimizing targeting to minimize off-target accumulation.
- Mechanism of action: While the study demonstrates P-selectin targeting and anti-inflammatory effects, a deeper dive into the precise molecular mechanisms by which CFNs exert these effects could be beneficial.
- Clinical translation: The study was conducted in animal models. Further preclinical and clinical trials are necessary to assess the efficacy and safety of CFNs in humans.
- Optimization of formulation: While the 3:1 ratio was selected, exploring other ratios and cross-linking agents could potentially further enhance stability and drug release control.
Summary updated